Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests secukinumab for back pain patients in korea

NCT ID NCT06905288

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

This study follows 70 Korean adults with ankylosing spondylitis who have never taken biologic drugs. They will receive secukinumab as part of routine care. Researchers will measure changes in disease activity and inflammation over time to see how effective the treatment is in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could confirm that secukinumab is a safe and effective first biologic option for Korean patients with ankylosing spondylitis.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (70 participants) and focused on a specific population, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The subjects are biologic-naive AS patients who are \<40 years old and have a time of less than 5 years since AS diagnosis.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria 2. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4 3. Subjects who have never used TNFi, JAKi, or IL-17i drugs before 4. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety 5. Subjects who have a time of less than 5 years since AS diagnosis 6. Subjects who are above the age of 18 years and below 40years old 7. Subjects who give informed consent form to participate in the study Exclusion Criteria: 1. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks) 2. Subjects who have congenital/traumatic spinal deformities 3. Subjects currently enrolled in other clinical studies 4. Subjects who have any contraindications to secukinumab treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis rheumatic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Jinju, Gyeongsangnam-do, 52727, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49201, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gwangju, 61469, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.